BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Compass Therapeutics readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Compass Therapeutics's drugs run\
 , from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05506943-10870@assetmemo.bio
DTSTAMP:20261121T005449Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:tovecimig: Phase 2/3 readout est. (NCT05506943)
DESCRIPTION:tovecimig\, phase 2/3\, Biliary Tract Cancer.\nStudy: A Study o
 f CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectab
 le Advanced\, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002
 )\nEstimated primary completion: 31 August 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/tovecimig#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT05506943
URL:https://assetmemo.bio/drug/tovecimig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
